Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0XR0B
|
||||
| Former ID |
DNCL003770
|
||||
| Drug Name |
SPI-205
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Phase 2 | [521523] | ||
| Company |
SPECTRUM pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | Tumor necrosis factor receptor superfamily member 16 | Target Info | Modulator | ||
| Pathway Interaction Database | p75(NTR)-mediated signaling | ||||
| Neurotrophic factor-mediated Trk receptor signaling | |||||
| Reactome | Axonal growth inhibition (RHOA activation) | ||||
| NRAGE signals death through JNK | |||||
| p75NTR negatively regulates cell cycle via SC1 | |||||
| Regulated proteolysis of p75NTR | |||||
| NADE modulates death signalling | |||||
| NRIF signals cell death from the nucleus | |||||
| p75NTR recruits signalling complexes | |||||
| NF-kB is activated and signals survival | |||||
| Axonal growth stimulation | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.